Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
October 17 2019 - 8:30AM
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of precisely targeted oncology therapies, today
announced that the Company will host a conference call and webcast
on Tuesday, October 29, 2019 at 4:30 pm ET (1:30 pm PT) to provide
a business update and report third quarter 2019 financial
results.
The conference call can be accessed by dialing 1-800-458-4121
(toll-free domestic) or 1-720-543-0206 (international) and using
the conference ID 8706779. The live webcast may be accessed via the
investor relations section of the Corvus website. A replay of the
webcast will be available on Corvus' website for 90 days.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of precisely
targeted oncology therapies. Corvus’ lead product candidates are
ciforadenant (CPI-444), a small molecule inhibitor of the A2A
receptor, and CPI-006, a humanized monoclonal antibody directed
against CD73 that exhibits immunomodulatory activity and blockade
of adenosine production. These candidates are being studied in
ongoing Phase 1 and 2 clinical trials in patients with a wide range
of advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort trial examining its activity both as a
single agent and in combination with an anti-PD-L1 antibody.
CPI-006 is being evaluated in a multicenter Phase 1/1b clinical
trial as a single agent, in combination with ciforadenant, and with
pembrolizumab. The Company’s third clinical program, CPI-818, an
oral, small molecule drug that has been shown to selectively
inhibit ITK, is in a multicenter Phase 1/1b clinical trial in
patients with several types of T-cell lymphomas. For more
information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus
Pharmaceuticals, Inc. 650-900-4522 LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure 213-262-9390
sseapy@w2ogroup.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024